Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease
- 1Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland
Abstract
Alzheimer’s disease (AD), as a chronic neurodegenerative disorder, leads to progressive dementia. About 60–80% of dementia cases are due to AD, and their incidence increases especially after the age of 65. AD is characterized by impaired memory, abnormal behavior, and impaired thinking process, which causes limitation of daily activities and a gradual loss of independence. The costs of all dementia cases are likely to reach $2 trillion in 2030 alone. Currently available pharmacological treatment of AD is, for the most part, not causal, and does not modify the course of the disease. The data search for procognitive drugs was carried out using the PUBMED and Clinical Science databases. Among the drugs with animal data and preliminary clinical trials, the following can be distinguished: fosgonimeton, blarcamesine, bezisterim, posiphen (buntanetap) and ACD856. As a rule, promising preclinical results were not confirmed in clinical trials. Some clinical expectations may be associated with posiphen and ACD856. Based on preclinical data, the following drugs seem promising: tenuigenin, JQ1, gemfibrozil, coumarin derivatives, ponicidin, salicin, calcaratarin D, new 1,3,5-triazines or 2-aminopyrymidine carboxamide derivatives, epimedium brevicornu flavonoids, and drugs affecting the glymphatic system. In general, the above-mentioned drugs counteract the pathologies leading to the occurrence of AD.
Related
- Exploring the potential targets and possible mechanisms of Shenqi Fuzheng Injection in the treatment of cancer-associated muscle wasting based on network pharmacology
- Targeting PAK1 Within Group I PAKs: Current Challenges and Pharmacological Perspectives.
- Gut microbiota and treatment response heterogeneity across pharmacological therapies for MASH
- In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions
- Advancing Alzheimer's Disease Treatment: Synergistic Ligand Combinations Targeting BACE1 via Multi-Ligand Simultaneous Docking
BibTeX
@article{miziak2026current,
title = {{Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease}},
author = {Barbara Miziak and Ryszard Pluta and Stanisław J. Czuczwar},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219959},
url = {https://www.mdpi.com/1422-0067/27/21/9959},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease
AU - Barbara Miziak
AU - Ryszard Pluta
AU - Stanisław J. Czuczwar
PY - 2026
DA - 2026/11/06
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219959
UR - https://www.mdpi.com/1422-0067/27/21/9959
AB - Alzheimer’s disease (AD), as a chronic neurodegenerative disorder, leads to progressive dementia. About 60–80% of dementia cases are due to AD, and their incidence increases especially after the age of 65. AD is characterized by impaired memory, abnormal behavior, and impaired thinking process, which causes limitation of daily activities and a gradual loss of independence. The costs of all dementia cases are likely to reach $2 trillion in 2030 alone. Currently available pharmacological treatment of AD is, for the most part, not causal, and does not modify the course of the disease. The data search for procognitive drugs was carried out using the PUBMED and Clinical Science databases. Among the drugs with animal data and preliminary clinical trials, the following can be distinguished: fosgonimeton, blarcamesine, bezisterim, posiphen (buntanetap) and ACD856. As a rule, promising preclinical results were not confirmed in clinical trials. Some clinical expectations may be associated with posiphen and ACD856. Based on preclinical data, the following drugs seem promising: tenuigenin, JQ1, gemfibrozil, coumarin derivatives, ponicidin, salicin, calcaratarin D, new 1,3,5-triazines or 2-aminopyrymidine carboxamide derivatives, epimedium brevicornu flavonoids, and drugs affecting the glymphatic system. In general, the above-mentioned drugs counteract the pathologies leading to the occurrence of AD.
SN - 1422-0067
ER -